ArticlePediatric blood & cancer2017

A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).

James I Geller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.